Using nanopore sequencing for faster breast cancer diagnosis in Tanzania
Official title: Nanopore Sequencing for Accelerating Breast Cancer Diagnosis in Tanzania: A Prospective Observational Study
Run by University of Bonn · NCT06633276 · Data updated 2026-11-12
This study is testing if a new method called nanopore sequencing can help doctors in Tanzania diagnose breast cancer faster and more accurately than the usual tests.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Bonn Academic / other |
| Locations | 1 site (Moshi) |
| Status | Recruiting |
| Started | September 30, 2025 |
| Main results expected | May 2027 |
| Study ends | December 2027 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT06633276 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with suspected breast cancer who are undergoing biopsy or surgical resection and can provide excess fresh tumor samples.
✕Probably not a fit
Patients who have already started therapy for breast cancer or are unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to evaluate the feasibility of nanopore sequencing as a diagnostic tool for breast cancer in Tanzania. It will compare the accuracy and turnaround time of nanopore sequencing against the current standard of care, which includes histopathology and biomarker analysis. By analyzing excess fresh tissue samples from patients with suspected breast cancer, the study seeks to demonstrate that nanopore sequencing can provide rapid and cost-effective results, potentially improving treatment planning in resource-limited settings.
Why it matters
Potential benefit: If successful, this approach could lead to quicker and more accurate breast cancer diagnoses, enhancing treatment outcomes for patients.
How similar studies have gone: While the use of nanopore sequencing in breast cancer diagnosis is a novel approach, similar studies in other contexts have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with suspected diagnosis of breast cancer undergoing biopsy or surgical resection after specialist consultation as per institutional guidelines * Excess fresh tumor sample * Written informed consent Exclusion Criteria: * Unable to provide informed consent * Patients who have already commenced therapy for BC (except for treatment other than biomedicine, e.g. herbal medicines)
Where it's running
-
Kilimanjaro Christian Medical Centre
Moshi, Tanzania Recruiting
Study contacts
- Principal investigator: Oliver Henke, MD — Section Global Health, University Hospital Bonn
- Study coordinator: Oliver Henke, MD
- Email: Oliver.Henke@ukbonn.de
- Phone: +49 (0) 228 287 51521
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ATUSA 3D automated breast ultrasound for suspicious breast lesions
This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.
-
SBRT with intratumoural pembrolizumab before neoadjuvant chemotherapy for high-risk breast cancer
This study will test whether a short course of focused radiation plus two injections of pembrolizumab into the tumor before chemotherapy helps people with high‑risk invasive breast cancer respond better to treatment.
-
Detecting cancer margins during breast surgery using advanced imaging technology
This study is testing a new imaging system that helps surgeons find cancerous tissue more accurately during breast cancer surgery to improve patient outcomes.
-
Confocal Histolog Scanner for checking margins during lumpectomy
This project will test whether using a confocal Histolog Scanner during lumpectomy helps surgeons find cancer at the edges of removed tissue and reduce the need for repeat operations in women having breast-conserving surgery.
-
Evaluating Circulating Tumor Cells in Breast Cancer Follow-up
This study is testing a new way to track cancer cells in the blood of breast cancer patients to see how their condition changes during treatment.
-
Using 68Ga-FAPi-46 PET/CT to study breast cancer
This study is testing a new imaging method using a special agent to see if it can help women with node-positive breast cancer get better information about their tumors before starting treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.